[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Processing failed - manual review needed

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years old
* Karnofsky index ≥80%
* Patients with operable head and neck cancer presenting histologically proven HNSCC (including Oral Cavity Cancer, Pharyngeal Cancer, Laryngeal Cancer)
* Patients with at least one nodal metastasis
* Patients scheduled for neck dissection
* SOC imaging (MRI, ceCT and 18F-FDG-PET/CT) performed as pre-surgery exams
* Written informed consent obtained

Exclusion Criteria:

* Known pregnancy or ongoing breast feeding
* Claustrophobia
* Severe renal insufficiency (GFR\<30 mL/min/1,73 m2)
* Liver enzymes (ALAT, ASAT)\>5 times the standard upper limit
* Bilirubin\>3 times the standard upper limit
* Hemoglobin\<8 g/dL
* Absolute neutrophil count\<1000/mm3
* Platelets\<75000/µL
* insufficient knowledge of project language, inability to give consent or to follow trial-associated procedures
* the patient makes use of his/her "right not to know" and refuses to be informed about incidental findings

Where it's running

• Centre hospitalier universitaire vaudois
  Lausanne, Canton of Vaud, Switzerland Recruiting

Study contacts

• Principal investigator: Niklaus Schaefer, MD — Centre Hospitalier Universitaire Vaudois
• Study coordinator: John O Prior, MD, PhD
• Email: john.prior@chuv.ch
• Phone: +41 21 314 4348

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Triple-drug neoadjuvant therapy for EGFR-positive locally advanced head and neck cancer

  This trial tests a three-drug neoadjuvant regimen (Becotatug Vedotin, Pucotenlimab, and Cisplatin) in adults with EGFR-positive, locally advanced head and neck cancer to see if it can shrink tumors before surgery or chemoradiotherapy.

  Recruiting at 2 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07814287

• CCR2 PET Imaging for Head and Neck Squamous Cell Carcinoma

  This trial tests whether Cu-64 DOTA-ECL1i PET/CT can reliably detect HNSCC in adults, including those with new locally advanced disease or suspected/confirmed recurrent/metastatic cancer.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07659678

• Nimotuzumab plus Immunotherapy and Chemotherapy before surgery for locally advanced head and neck cancer

  This phase 2 trial tests whether adding nimotuzumab to immunotherapy and chemotherapy before surgery helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07601737

• Re-irradiation with chidamide for recurrent head and neck squamous cell carcinoma

  This trial will test whether adding the drug chidamide to repeat radiation is safe and tolerable for adults whose head and neck squamous cell carcinoma has returned after prior radiotherapy.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07545967

• Dose-finding of EXS74539 (REC-4539) in select solid tumors

  This study will try different doses of the experimental drug EXS74539 in adults with select solid tumors to find a safe and tolerable dose.

  Recruiting at 3 sites Phase 1 Exscientia AI Limited · Los Angeles, California and 2 other locations · NCT07517198

• Ficerafusp alfa plus pembrolizumab before surgery for resectable head and neck squamous cell carcinoma

  This trial will test whether giving ficerafusp alfa together with pembrolizumab before surgery helps people with PD‑L1–positive, resectable, high‑risk head and neck squamous cell carcinoma.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07465276

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.